ParenteralDosed ingredient Cosmetic cross-reference

Dexpanthenol

CAS 81-13-0

Dexpanthenol (CAS 81-13-0) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 1,990 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral / FAERS
Adverse signals
1,990
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Dexpanthenol
CAS Number
81-13-0
UNII
1O6C93RI7Z
InChIKey
SNPLKNRPJHDVJA-ZETCQYMHSA-N
ChEMBL ID
CHEMBL1200979
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural productparenteral
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200979 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE ChEMBL 36 activities + assays 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 28378.65 nM 32 -
- IC50 19976.309999999998 nM 1 -
SOURCE DrugCentral 2023 / FAERS disproportionality 38 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Pneumonia aspiration 116 226.72 10035669
Gastrooesophageal reflux disease 132 204.464 10017885
Coma 108 164.759 10010071
Somnolence 140 127.813 10041349
Tumour pain 15 48.014 10045171
Underdose 35 43.846 10057362
Female genital tract fistula 16 36.076 10061149
Anterior segment ischaemia 6 34.711 10076692
Incorrect route of product administration 29 33.032 10081202
Pulmonary vein occlusion 6 30.695 10068690
Vaginal flatulence 11 29.102 10064227
Febrile bone marrow aplasia 18 28.896 10053213
Chronic sinusitis 17 27.28 10009137
Breast cancer metastatic 15 26.565 10055113
Anaemia 101 26.496 10002034
Intestinal haemorrhage 13 26.324 10059175
Generalised oedema 21 24.842 10018092
Toxic epidermal necrolysis 25 24.82 10044223
Optic nerve disorder 8 23.86 10061322
General physical health deterioration 70 23.138 10049438
Lagophthalmos 6 22.879 10023683
Proctitis 12 22.626 10036774
Radiculopathy 13 21.702 10037779
Hepatic cirrhosis 22 21.496 10019641
Metastases to meninges 9 20.079 10051696
Face oedema 18 19.336 10016029
Peripheral swelling 3 19.231 10048959
Vaginal discharge 11 18.927 10046901
Venous thrombosis limb 9 18.89 10061408
Pain of skin 14 18.808 10033474
Oral candidiasis 18 17.732 10030963
Stevens-Johnson syndrome 20 17.44 10042033
Appendicolith 10 16.976 10074458
Toxicity to various agents 9 16.684 10070863
Product use issue 3 16.627 10076309
Retinal degeneration 6 16.322 10038845
Breast cancer 20 15.924 10006187
Analgesic therapy 5 15.101 10053469

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE RxNorm drug names 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Dexpanthenol 22701 SU MTHSPL
DEXPANTHENOL 22701 SU MTHSPL
dexpanthenol 22701 IN RXNORM
SOURCE SIDER side-effect resource 22 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal colic dexpanthenol LLT C0232488
Abdominal pain dexpanthenol PT C0000737
Agitation dexpanthenol LLT C0085631
Agitation dexpanthenol PT C0085631
Dermatitis dexpanthenol LLT C0011603
Dermatitis dexpanthenol PT C0011603
Diarrhoea dexpanthenol LLT C0011991
Diarrhoea dexpanthenol PT C0011991
Dyspnoea dexpanthenol LLT C0013404
Dyspnoea dexpanthenol PT C0013404
Hypersensitivity dexpanthenol LLT C0020517
Hypersensitivity dexpanthenol PT C0020517
Hypotension dexpanthenol LLT C0020649
Hypotension dexpanthenol PT C0020649
Paraesthesia dexpanthenol PT C0030554
Pruritus dexpanthenol LLT C0033774
Pruritus dexpanthenol PT C0033774
Tingling sensation dexpanthenol LLT C2242996
Urticaria dexpanthenol LLT C0042109
Urticaria dexpanthenol PT C0042109
Vomiting dexpanthenol LLT C0042963
Vomiting dexpanthenol PT C0042963
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Dexpanthenol used for in pharmaceutical contexts?

Dexpanthenol (CAS 81-13-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Dexpanthenol?

Dexpanthenol has 1,990 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pneumonia aspiration, Gastrooesophageal reflux disease, Coma, Somnolence, Tumour pain. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Dexpanthenol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for PANTHENOL with EU status "permitted".

What clinical phase is Dexpanthenol in?

Dexpanthenol is rendered with ChEMBL max phase 4 (approved).